Cutler Group LP Solid Biosciences Inc. Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 26, 2021	BUY	$5.37 - $10.72 $3,759 - $7,504	700 New	700 $3,000
Q4 2020 Jan 21, 2021	SELL	$3.08 - $7.79 $1,848 - $4,674	-600 Closed	0 $0
Q2 2020 Jul 22, 2020	SELL	$2.1 - $3.42 $5,880 - $9,576	-2,800 Reduced 82.35%	600 $1,000
Q1 2020 May 07, 2020	SELL	$2.31 - $4.43 $231 - $443	-100 Reduced 2.86%	3,400 $8,000
Q4 2019 Feb 06, 2020	BUY	$2.82 - $12.9 $6,768 - $30,960	2,400 Added 218.18%	3,500 $15,000
Q3 2019 Oct 28, 2019	SELL	$4.33 - $11.64 $3,464 - $9,312	-800 Reduced 42.11%	1,100 $11,000
Q2 2019 Aug 09, 2019	SELL	$4.6 - $10.13 $7,359 - $16,208	-1,600 Reduced 45.71%	1,900 $10,000
Q1 2019 May 10, 2019	BUY	$7.19 - $32.37 $22,289 - $100,346	3,100 Added 775.0%	3,500 $32,000
Q4 2018 Feb 05, 2019	BUY	$21.32 - $46.34 $8,528 - $18,536	400 New	400 $10,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $53.2M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.